-
Professor Wenming Chen: Advances in the Application of Bispecific Antibodies in Multiple Myeloma | 2026 Cross-Strait Hematology Academic Conference
The treatment landscape for multiple myeloma continues to evolve with successive advances in immune-targeted therapies. As a novel class of immunotherapeutic agents, bispecific antibodies have helped address major treatment challenges in patients with relapsed or refractory disease and have become a key focus of research in multiple myeloma. The 2026 Cross-Strait Hematology Academic Conference was…
-
CSCO DocX TALK | Upholding Core Principles and Driving Innovation: Professor Heinz-Josef Lenz and HUTCHMED Discuss the Globalization of China’s Innovative Oncology Drugs
The 2026 Chinese Society of Clinical Oncology (CSCO) Annual Meeting showcased cutting-edge advances in oncology worldwide, with China’s innovative drug development attracting particular attention. China has become an increasingly important force in global cancer research and treatment. During the meeting, Oncology Frontier invited Professor Heinz-Josef Lenz of USC Norris Comprehensive Cancer Center and Mr. George…
-
Professor Li Wang: First-Line Treatment Landscape and Controversies in MCL in the BTK Inhibitor Era | 2026 China-France Scientific Symposium on Hematology and Immunology
The 2026 China-France Scientific Symposium on Hematology and Immunology was held in Beijing from September 11 to 13, 2026. Building on the longstanding tradition of hematology exchanges between China and France, this year’s meeting expanded its scope to the intersection of hematology and immunology, bringing together renowned experts from both countries to explore scientific advances…
-
Getting to the Bottom of the Debate 2.0 | Metastatic Renal Cell Carcinoma: Extrapolating Second-Line Evidence and Individualizing First-Line Dual Immunotherapy Versus Immunotherapy–TKI Combinations—A Debate Between Professors Xuewen Jiang and Hailiang Zhang
Systemic treatment for metastatic renal cell carcinoma (mRCC) is evolving rapidly in the era of targeted therapy and immunotherapy combinations, bringing two major clinical questions to the forefront.
-
Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou
Treatment options for metastatic castration-resistant prostate cancer (mCRPC) are expanding rapidly. However, two major challenges remain in clinical decision-making: how to adjust treatment following oligoprogression and how to optimize the sequencing of precision therapies.
-
Professor Dingwei Ye and Professor Xiaojie Bian: Breaking Through Treatment Challenges in mCRPC with Sacituzumab Tirumotecan Plus Immunotherapy for Durable Survival Benefits
Patients with metastatic castration-resistant prostate cancer (mCRPC) who experience disease progression following novel endocrine therapy have very limited treatment options, presenting a major clinical challenge. In recent years, China has made substantial advances in innovative drug development, continuously reshaping treatment strategies. Novel TROP2 antibody-drug conjugates (ADCs), represented by sacituzumab tirumotecan, have demonstrated promising potential in…
-
2026 CSCO | Professor Dingwei Ye and Professor Yao Zhu: Novel Breakthrough with a China-Developed TROP2 ADC—Sacituzumab Tirumotecan Demonstrates Significant Clinical Value in Advanced Urothelial Carcinoma
In recent years, treatment for urothelial carcinoma has advanced rapidly, with combination therapy involving targeted agents and immunotherapy significantly improving survival outcomes in patients with advanced disease. The CSCO Guidelines for the Diagnosis and Treatment of Urothelial Carcinoma have continued to incorporate emerging evidence, further enriching the standardized treatment framework. However, for most patients whose…
Connecting Medical Expertise through Media
